Publications
Detailed Information
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, J. O. | - |
dc.contributor.author | Lee, K. W. | - |
dc.contributor.author | Oh, D. Y. | - |
dc.contributor.author | Kim, J. H. | - |
dc.contributor.author | Im, S. A. | - |
dc.contributor.author | Kim, T. Y. | - |
dc.contributor.author | Bang, Y. J. | - |
dc.date.accessioned | 2021-01-31T11:10:26Z | - |
dc.date.available | 2021-01-31T11:10:26Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2009-08 | - |
dc.identifier.citation | Annals of Oncology, Vol.20 No.8, pp.1402-1407 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 119421 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173078 | - |
dc.description.abstract | Patients and methods: From September 2003 to July 2007, we enrolled patients with HCC who had more than one measurable extrahepatic metastatic lesion. Patients received oral capecitabine (2000 mg/m(2)/day) with a schedule of 2 weeks on and 1 week off and cisplatin (60 mg/m(2)) on the first day of the 3-week cycle. Results: The study cohort consisted of 32 patients with a median age of 53 years. Overall response rate was 6.3% and disease control rate was 34.4%. The median time to progression (TTP) was 2.0 months [95% confidence interval (CI) 1.5-2.4] and the median overall survival (OS) time was 12.2 months (95% CI 6.5-17.8). The grade 3/4 hematologic toxic effects included thrombocytopenia (7.6%), neutropenia (4.3%) and anemia (2.1%). The grade 3/4 non-hematologic toxic effects included elevated hepatic aminotransferase (12.9%), jaundice (3.2%), mucositis (3.2%) and nausea (3.2%). There was no treatment-related mortality. Conclusions: Based on the observed response rate and TTP, XP combination chemotherapy showed modest antitumor efficacy in patients with metastatic HCC as systemic first-line treatment. However, XP combination chemotherapy showed tolerable toxicity and demonstrated favorable OS time. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/annonc/mdp010 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000268806700015 | - |
dc.identifier.scopusid | 2-s2.0-69449106391 | - |
dc.citation.endpage | 1407 | - |
dc.citation.number | 8 | - |
dc.citation.startpage | 1402 | - |
dc.citation.volume | 20 | - |
dc.identifier.sci | 000268806700015 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Oh, D. Y. | - |
dc.contributor.affiliatedAuthor | Kim, J. H. | - |
dc.contributor.affiliatedAuthor | Im, S. A. | - |
dc.contributor.affiliatedAuthor | Kim, T. Y. | - |
dc.contributor.affiliatedAuthor | Bang, Y. J. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | INFUSION | - |
dc.subject.keywordPlus | CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | capecitabine | - |
dc.subject.keywordAuthor | cisplatin | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | metastasis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.